A recent study by the Mayo Clinic suggests that a blood test measuring phosphorylated tau 217 (p-tau217) might help predict cognitive decline in older adults within five to ten years. The research involved 2,178 cognitively unimpaired participants aged 60 to 90 and found that older age increases the risk of mild cognitive impairment at elevated p-tau217 levels. While the test could be less invasive than current methods, it is not yet suitable for routine screening as there are no approved treatments for asymptomatic individuals with Alzheimer’s pathology.
Key facts
- The study involved 2,178 adults aged 60 to 90.
- Higher age correlates with increased risk of cognitive decline.
- A 65-year-old has a 6% risk of mild cognitive impairment, compared to 37% for an 85-year-old.
- The test is not yet ready for routine screening of asymptomatic individuals.
- No approved treatments exist for those with Alzheimer’s pathology but no symptoms.
A short AI summary in our own words. The reporting belongs to Fox News — Latest; we don't reproduce it.